12.03.2014 • NewsBayerDede Willamshealthcare

Bayer to Invest More Than €500 Million in Haemophilia Pipeline

BayerHealthcare plans to invest more than €500 million at its sites in Wuppertal and Leverkusen, Germany, to expand capacity for production of its recombinant factor VIII haemophilia drug.

Investigational therapy options for haemophilia, including a plama protein-free upgrade of the Factor VIII drug Kogenate and a long-acting recombinant FVIII are currently in Phase III chemical trials. In February, Bayer announced positive results from the PROTECT VIII trials evaluating its site-specific PEGylated recombinant FVIII drug.

The investment is one of the largest in the history of Bayer HealthCare said the sub-group's CEO Oliver Brandicourt. It will create around 500 new jobs at the two sites up to 2020.

Establishing a base in Germany for Kogenate, currently manufactured exclusively in Berkeley, California, in the U.S., will help the company prepare for production of the expected new therapy options and address the growing demand in this therapeutic area, Brandicourt said.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read